Kamath Ganesh S, Steinberg Jonathan S
Al-Sabah Arrhythmia Institute and Division of Cardiology, St. Luke's and Roosevelt Hospitals, Columbia University College of Physicians & Surgeons, New York, NY USA.
J Atr Fibrillation. 2011 Sep 30;4(3):334. doi: 10.4022/jafib.334. eCollection 2011 Sep-Nov.
Cardiac resynchronization therapy (CRT) is an important advance for the treatment of end--stage heart failure (HF). About 15-50% of HF is complicated by atrial fibrillation (AF) and associated with worsened outcomes. Meta-analyses from observational studies suggest that patients with AF derive similar benefits to CRT as patients in sinus rhythm (SR). The presence of AF, however, may interfere with optimal delivery of CRT due to competition with biventricular (BiV) capture by conducted beats. Atrioventricular junction (AVJ) ablation with permanent pacing eliminates interference by conducted beats and provides complete BiV capture. Catheter ablation of AF is an alternative to antiarrhythmic drugs to maintain sinus rhythm in patients with AF and HF. Randomized trial comparing catheter ablation, AVJ ablation and pharmacologic therapy are needed.
心脏再同步治疗(CRT)是终末期心力衰竭(HF)治疗的一项重要进展。约15%-50%的HF合并心房颤动(AF),且与预后恶化相关。观察性研究的荟萃分析表明,AF患者接受CRT与窦性心律(SR)患者获得的益处相似。然而,AF的存在可能会干扰CRT的最佳传递,因为传导的搏动会与双心室(BiV)夺获竞争。房室结(AVJ)消融并永久起搏可消除传导搏动的干扰,并实现完全的BiV夺获。导管消融AF是AF合并HF患者维持窦性心律的抗心律失常药物的替代方法。需要进行比较导管消融、AVJ消融和药物治疗的随机试验。